Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

FDC LTD. - 531599 - Board Meeting Intimation for Un-Audited Standalone & Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2023.

 FDC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2023 ,inter alia, to consider and approve the Unaudited Standalone & Consolidated Financial Results of the Company for the Quarter ended June 30, 2023. Further, in accordance with Code of Conduct for prevention of Insider Trading adopted by the Company, SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 and vide our Intimation letter dated June 30, 2023, the Trading Window of the Company has been closed for all the Directors and Designated Persons, Connected Persons and their Immediate Relatives from Saturday, July 01, 2023 till 48 hours after the declaration of Unaudited Financial Results for the quarter ended June 30, 2023.
01-08-2023
Bigul

FDC LTD. - 531599 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

 Please find enclosed herewith Scrutinizer Report for voting results pursuant to Regulation 44(3) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
15-07-2023
Bigul

FDC LTD. - 531599 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot

 Please find enclosed Voting Results pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
15-07-2023
Bigul

FDC LTD. - 531599 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Please find enclosed certificate in terms of Regulation 74(5) of the securities exchanges Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2023.
10-07-2023
Bigul

FDC LTD. - 531599 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (LODR) Regulations, 2015, we hereby submit information regarding report from shareholders for loss of share certificates and request for issue of duplicate share certificate.
01-07-2023
Bigul

FDC LTD. - 531599 - Closure of Trading Window

 Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 and in compliance with the Code of Conduct of the Company to Regulate, Monitor and Report Trading by Designated Persons, the Trading Window for dealing in Securities of FDC Limited ("the Company") for all Designated Persons, Connected Persons and their Immediate Relative(s), shall remain closed from Saturday, July 1, 2023 until 48 hours after the declaration of the Unaudited Financial Results of the Company for the quarter ended June 30, 2023.
30-06-2023

Govt planning more crackdowns on vitamin and mineral combination drugs

 The government banned 14 FDCs in June that affected around Rs 824 crore of the domestic pharmaceuticals market
28-06-2023

HC seeks Centre's stand on challenge to ban on fixed dose combination drugs

 The Delhi High Court has sought the stand of the Centre on a petition by a pharmaceutical company challenging the government's decision to ban manufacture, sale and distribution for human use certain Fixed Dose Combination (FDC) drugs. FDC drugs are those which contain a combination of two or more active pharmaceutical ingredients (APIs) in a fixed ratio. While issuing notice on three petitions by Glenmark Pharmaceuticals Ltd against the ban, the court directed the FDC drugs produced by the petitioners that are already in the distribution channel shall not be withdrawn and no coercive steps will be taken against them. The petitioner was producing FDC drugs under the brand names Glencoff Q, Ascodex Dx Syrup, Ascoril-C Syrup and others, the court noted. The government had announced a ban on 14 FDC drugs on June 2 this year on the recommendations of an expert committee, saying there was "no therapeutic justification" for these medicines and they may involve "risk" to people. The cour
19-06-2023
Bigul

FDC LTD. - 531599 - US - FDA Inspection At Company'S Manufacturing Facility Located At Roha, Raigad - Receipt Of Establishment Inspection Report (EIR) With No Action Indicated ( NAI )

 This is further to the intimation given by the Company dated March 27, 2023, the U.S. Food and Drug Administration (FDA) had conducted an inspection at Company's manufacturing facility located at, 19 & 20/2 Plot, MIDC Industrial Area, Dhatav, Roha, Raigad District, Maharashtra, India from 20th March, 2023 to 24th March, 2023. FDA has determined that the inspection classification of this facility is "no action indicated" ("NAI"). Based on this inspection, this facility is considered to be in an acceptable state of compliance with regards to Current Good Manufacturing Practice (CGMP). FDA has concluded that this inspection is ''''Closed'''' and a copy of the narrative portion of the Establishment Inspection Report (EIR) has been issued.
15-06-2023
Bigul

FDC LTD. - 531599 - US - FDA Inspection At Company'S Manufacturing Facility Located At Waluj, Aurangabad- Receipt Of Establishment Inspection Report (EIR) With No Action Indicated ('NAI')

 This is further to the intimation given by the Company dated February 13, 2023 ,the U.S. Food and Drug Administration (FDA) had conducted an inspection at Company's manufacturing facility located at B-8 MIDC Industrial Area, Waluj District, Aurangabad, Maharashtra State, from 6th February, 2023 to 12th February, 2023. FDA has determined that the inspection classification of this facility is "no action indicated" ("NAI"). Based on this inspection, this facility is considered to be in an acceptable state of compliance with regards to Current Good Manufacturing Practice (CGMP). FDA has concluded that this inspection is ''''closed'''' and a copy of the narrative portion of the Establishment Inspection Report (EIR) has been issued.
15-06-2023
Next Page
Close

Let's Open Free Demat Account